Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Goldman Sachs Downgrades Calyxt Inc. (CLXT) to Neutral Following Q4 EPS
March 5, 2020 7:15 PM ESTGoldman Sachs analyst Adam Samuelson downgraded Calyxt Inc. (NASDAQ: CLXT) from Buy to Neutral with a price target of $7.00 (from $19.00).
For an analyst ratings summary and ratings history on Calyxt Inc. click here. For more ratings news on Calyxt Inc. click here.
Shares of Calyxt Inc. closed at $6.56 yesterday.
... MoreCellectis (CLLS) Tops Q4 EPS by 19c
March 4, 2020 4:33 PM ESTCellectis (NASDAQ: CLLS) reported Q4 EPS of ($0.54), $0.19 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $3.08 million versus the consensus estimate of $4.95 million.
For earnings history and earnings-related data on Cellectis (CLLS) click here.
... More